Alexion Pharmaceuticals CEO Ludwig Hantson's 2018 pay rises 8% to $16M
Alexion Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: March 26, 2019
Alexion Pharmaceuticals reported fiscal year 2018 executive compensation information on March 26, 2019.
In 2018, six executives at Alexion Pharmaceuticals received on average a compensation package of $7.5M, a 5% increase compared to previous year.
Ludwig Hantson, Chief Executive Officer, received $16M in total, which increased by 8% compared to 2017. 75% of Hantson's compensation, or $12M, was in stock awards. Hantson also received $2.9M in non-equity incentive plan, $1.2M in salary, as well as $25K in other compensation.
Julie O'Neill, Former Executive Vice President of Global Operations, received a compensation package of $7.7M, which increased by 66% compared to previous year. 64% of the compensation package, or $5M, was in stock awards.
Paul Clancy, Chief Financial Officer, earned $5.5M in 2018, a 52% decrease compared to previous year.
Anne-Marie Law, Executive Vice President, Chief Patient and Employee Experience Officer, received $5.3M in 2018, which increases by 58% compared to 2017.
Brian Goff, Executive Vice President and Chief Commercial Officer, earned $4.9M in 2018, a 19% increase compared to previous year.
John Orloff, Executive Vice President, Head of Research & Development, received $4.9M in 2018, which increases by 34% compared to 2017.
Related executives
Ludwig Hantson
Alexion Pharmaceuticals
Chief Executive Officer
Paul Clancy
Alexion Pharmaceuticals
Chief Financial Officer
Brian Goff
Alexion Pharmaceuticals
Executive Vice President, Chief Commercial and Global Operations Officer
Anne-Marie Law
Alexion Pharmaceuticals
Executive Vice President, Chief Human Experience Officer
John Orloff
Alexion Pharmaceuticals
Executive Vice President, Head of Research and Development
Julie O'Neill
Alexion Pharmaceuticals